Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?

Blood. 2009 Jun 11;113(24):6263-4. doi: 10.1182/blood-2009-04-213892.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / immunology
  • Antineoplastic Agents / therapeutic use*
  • Epstein-Barr Virus Infections / therapy
  • Epstein-Barr Virus Infections / virology*
  • Hematopoietic Stem Cell Transplantation
  • Herpesvirus 4, Human / physiology*
  • Humans
  • Lymphoproliferative Disorders / therapy
  • Lymphoproliferative Disorders / virology*
  • Rituximab
  • Transplantation, Homologous
  • Virus Activation*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab